Drug Trial Radar · NCT00099502
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Last checked: Nov 20, 2026Latest source record: Dec 19, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,244
Actual
Start
Nov 2003
Primary completion
Not stated
Study completion Aug 2007
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 16, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine * whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms * whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)Drug
250mcg administered s.c. every other day
Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)Drug
500mcg administered s.c. every other day
CopaxoneDrug
20 mg administered s.c. once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hazard ratio for relapsesTime frame: During the first and during the second 52 weeks
Locations
199 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Cullman, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Berkeley, California
Site not named
La Jolla, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
Englewood, Colorado
Site not named
Fort Collins, Colorado
Site not named
Wilmington, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Indianapolis, Indiana
Site not named
Des Moines, Iowa
Site not named
Kansas City, Kansas
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Shreveport, Louisiana
Site not named
Detroit, Michigan
Site not named
Duluth, Minnesota
Site not named
St Louis, Missouri
Site not named
Henderson, Nevada
Site not named
Reno, Nevada
Site not named
Lebanon, New Hampshire
Site not named
New Brunswick, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Mineola, New York
Site not named
Rochester, New York
Site not named
Stony Brook, New York
Site not named
Charlotte, North Carolina
Site not named
Durham, North Carolina
Site not named
High Point, North Carolina
Showing 40 of 199 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.